AI Article Synopsis
- In a double-blind, randomized study of 129 patients undergoing prostate surgery, those treated with 1 g of ceftriaxone experienced significantly fewer postoperative urinary tract infections compared to those receiving a placebo.
- Of the placebo group, 12.7% developed infections, while only 3% of the ceftriaxone group were affected, with a statistically significant result (p < 0.05).
- The study concluded that a single preoperative dose of ceftriaxone is both safe and effective in preventing infections during transurethral resection of the prostate.
Article Abstract
One hundred twenty-nine patients undergoing transurethral resection of the prostate were treated preoperatively with either 1 g of ceftriaxone or placebo in a double-blind, randomized study. Sixty-three patients received placebo and 66 received ceftriaxone. Postoperative urinary tract infections developed in eight placebo-treated patients, for a 12.7 percent failure rate, compared with two ceftriaxone-treated patients, for a 3 percent failure rate. The difference in rates of infection was statistically significant (p less than 0.05). No adverse effects due to treatment were noted. The high rate of postoperative infection in the placebo-treated group indicates that maintenance of sterility during and after this operative procedure is a problem. A single 1 g prophylactic preoperative dose of ceftriaxone was safe and efficacious in reducing the rate of postoperative infection after transurethral resection of the prostate.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!